Date: 2026-02-23 (updated; prior version 2026-02-21) Quarter: Q4 FY25 (Oct–Dec 2025) Market cap: ~$3.3B | EV/TTM Rev: ~5.6x | Revenue growth: +45.5% YoY (Q4), +51% FY25 | Rule of 40: 81
HNGE delivered an exceptional Q4 and FY25. Revenue beat by 13.9M(8.70.49 vs 0.14), andthecompanyachievedfirstGAAPoperatingprofitabilitytwoquartersaheadofexpectations.Ruleof40of81iselite − tier.Thestocktradesat5.6xTTMrevenue—roughlyhalfthemultiplejustifiedbythegrowth/marginprofile.FY26guidanceof25171–173M, +39% YoY) makes the 25% full-year guide mathematically implausible without dramatic H2 deceleration that the leading indicators do not support. Conviction: 4/5. Primary risk is real growth deceleration as the ASO market matures and non-ASO economics remain unproven at scale.
| Criterion | Threshold | Actual | Status |
|---|---|---|---|
| Revenue YoY growth | >30% (>40% preferred) | +45.5% Q4, +51% FY25 | PASS |
| Gross margin | >60% (>70% preferred) | 85% Non-GAAP | PASS |
| Revenue per quarter | >$50M | $170.7M | PASS |
| Data availability | 4+ quarters | 12 quarters (pre-IPO estimated) | PASS |
| Share dilution | <10% annual | <3% SBC dilution | PASS |
| GAAP profitability trajectory | Improving or positive | First GAAP op profit Q4 FY25 | PASS |
All six criteria pass. Pre-IPO quarters (FY23) estimated from S-1 disclosures. Post-IPO data (Q2–Q4 FY25) is fully audited.
| Factor | Rating | Detail |
|---|---|---|
| Growth | Strong | +45.5% Q4 YoY; +51% FY25 full year. Absolute revenue $170.7M/Q. |
| Trajectory | Decelerating (managed) | 55% → 53% → 45.5% over last 3 quarters. Base-effect driven, not demand-driven. Client adds at all-time high (+270 in Q4). |
| Margins | High / Expanding | 85% Non-GAAP GM (ATH); 28% Non-GAAP OpM (record); 36% FCF margin Q4. GAAP op profit positive Q4 first time. |
| Dominance | Strong | 53% Fortune 100 penetration. Win rate ATH per management. 21 peer-reviewed studies vs Sword ~5–7. Largest MSK dataset. |
| Valuation | Cheap | 5.6x TTM revenue; 18.3x TTM FCF; 6.7x TTM gross profit. Half the multiple of comparable-quality peers. |
| Special | Present | $665M buyback = 20% of market cap. Post-IPO mispricing. Non-ASO growing 130% YoY. Robin AI driving structural GM expansion. |
| Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cal. date | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 |
| Revenue ($M) | $60.0 | ~$67 | ~$71 | ~$81 | ~$82 | ~$90 | ~$99 | ~$117 | ~$125 | ~$140 | ~$152 | $170.7 |
| YoY% | — | — | — | — | ~+37% | ~+34% | ~+39% | ~+45% | ~+52% | +55% | +53% | +45.5% |
| QoQ% | — | +12% | +6% | +14% | +1% | +10% | +10% | +18% | +7% | +12% | +9% | +12.3% |
Q1–Q4 FY23 and FY24 estimated from S-1 disclosures and derived from known growth rates. FY25 total confirmed: 587.9M(+51389M). FY24 total derived from FY25 ÷ 1.51.
| Q2 FY25 | Q3 FY25 | Q4 FY25 | FY25 Full Year | |
|---|---|---|---|---|
| Non-GAAP GM% | ~83% | ~84% | 85% | ~84% |
| Non-GAAP OpM% | ~24% | ~26% | 28% | ~20% |
| Non-GAAP EPS | ~$0.32 | ~$0.40 | $0.49 | ~$1.40 |
| FCF margin% | ~30% | ~32% | 36% | ~31% |
| Rule of 40 | ~79 | ~79 | 81.5 | 81 |
GAAP: Q4 FY25 first GAAP operating profit. Net margin 18.8% GAAP in Q4. Trajectory: GAAP OpM moved from ~-61% (Q1 FY23) to approximately +3–5% (Q4 FY25).
Entering Q4 FY25 earnings (reported ~Feb 12, 2026):
| Metric | Prior Belief (consensus / guidance) | Actual | Verdict |
|---|---|---|---|
| Q4 Revenue | $155–157M (company guide midpoint) | $170.7M | +$13.9M / +8.9% beat |
| Non-GAAP OpM | 20–22% (management guide) | 28% | +600–800 bps above high end |
| Non-GAAP EPS | $0.14 (consensus) | $0.49 | +250% beat |
| Gross margin | 83–84% | 85% | 100 bps above prior peak |
| Client adds | ~200–230 (run-rate) | +270 | All-time high quarter |
| GAAP profitability | H2 FY26 (expected) | Q4 FY25 | Two quarters early |
| FY26 guide | 35–40% (bull case) | 25% guided | Deliberate sandbag |
| Q1 FY26 guide | — | $171–173M (+39% YoY) | Inconsistent with 25% FY guide |
Delta assessment: The EPS beat (250%) and margin beat (600+ bps) were the real surprises. GAAP profitability arrived two quarters early. The FY26 guide of 25% is the one number that disappointed — but the Q1 guide (+39% YoY) immediately undermines it. If Q1 delivers $171–173M, reaching only $732–742M for the full year requires H2 growth to average ~17% YoY — an order-of-magnitude deceleration inconsistent with any leading indicator. I model 33–38% actual FY26 growth based on the beat pattern and leading indicator strength.
| Indicator | Q2 FY25 | Q3 FY25 | Q4 FY25 | Trend |
|---|---|---|---|---|
| TTM Billings | — | — | $671M (+43.6% YoY) | Accelerating |
| Client adds (QoQ) | — | — | +270 (ATH) | Accelerating |
| Total clients | 2,490 | 2,560 | 2,830 | Consistent |
| Contracted lives | ~19.8M | ~22M | 24.6M (+24% YoY) | Steady |
| Members (enrolled) | ~660K | ~720K | 782,890 (+47% YoY) | Accelerating |
| NDR / NRR | >110% | >110% | >110% | Stable at floor |
| Client retention | 97% | 97% | 97% | Flat (high) |
| Partner retention | 100% | 100% | 100% | Perfect |
| Yield (members/contracted lives) | ~3.7% | ~3.8% | 3.9% | Slow expansion |
Bullish divergence: TTM billings at +43.6% YoY is tracking above reported revenue growth (45.5%), consistent with a small acceleration in billings that will flow into revenue recognition in FY26. Client adds at ATH (+270 vs prior run-rate ~200) will convert to revenue over 6–12 months. Members growing +47% YoY against contracted lives +24% means yield is expanding — more enrolled per contracted life. All three signals point to FY26 actual growth well above the 25% guided.
Non-ASO flag (key watch item): Non-ASO revenue (Medicare Advantage, FEP) was +130% YoY as of Q3 FY25. Management deflected on Q4 non-ASO specifics. If non-ASO reaches 15–20% of revenue in FY26, it materially extends the growth runway beyond ASO saturation risk.
(Source: stages/scuttlebutt/HNGE/2026-02-23.md — first dedicated scuttlebutt run)
Customer sentiment (mixed positive):
Employee sentiment (concerning signal):
Competitive landscape:
Product / technology:
Management:
Hiring:
| Metric | Current (Dec-25) | Peer Median | Assessment |
|---|---|---|---|
| EV/TTM Revenue | 5.6x | 8–12x (digital health comps) | Cheap |
| EV/TTM Gross Profit | 6.7x | 10–15x | Cheap |
| EV/TTM FCF | 18.3x | 25–35x | Cheap |
| P/E (Non-GAAP TTM) | ~22x | 30–50x | Cheap |
| Market cap | ~$3.3B |
Peer benchmarks:
Rule of 40 framework: Score of 81 historically correlates with 15–20x revenue multiple for established public companies. At 5.6x, HNGE trades at 28–37% of the framework-implied fair value. Even applying a 50% discount for post-IPO stage and single-product concentration → fair range 8–10x TTM revenue = 4.7–5.9Bmarketcap = 40–803.3B.
Buyback signal: $665M authorized = 20% of market cap at IPO price. Board-sanctioned signal that shares are materially undervalued. Companies with strong FCF and a concrete buyback program provide a floor mechanism.
Secular trend: Digital MSK health. MSK conditions are the #1 driver of employer healthcare costs in the US (~$350B/year). Digital-first AI-augmented delivery has 10–20× better unit economics vs traditional PT. Structural tailwind as employers demand cost reduction and outcome accountability.
Platform evolution trajectory:
TAM penetration: 24.6M contracted lives vs ~180M commercially insured US lives = 13.7% penetration. Adding Medicare Advantage (65M lives) → ~10% penetration of combined TAM. Substantial runway remains.
Moat durability: Strong. The 21 peer-reviewed studies, proprietary dataset, and hardware+digital+in-person model create a 3–5 year replication barrier. Sword's IPO will test this — if HNGE win rates hold above 70% through FY26, the moat thesis is confirmed.
Guided deceleration is real. Even with conservatism, FY26 actual growth may settle at 33–38%, not 50%+. Enterprise ASO market saturation is a real ceiling. The growth story depends on non-ASO (unproven at scale) and HingeSelect (undisclosed utilization) filling the gap.
Sword Health IPO and competitive intensification. A Sword IPO gives capital for clinical validation, sales headcount, and potential pricing pressure. HNGE's 80% win rate is the key metric to watch — any deterioration below 70% is a warning sign.
Post-IPO insider selling. Lockup expired ~Nov 2025. Pre-IPO shareholders (venture, founders) may be systematic sellers. Float supply overhang can suppress price despite fundamentals for 12–18 months.
Non-ASO economics unproven at scale. Medicare Advantage reimbursement, enrollment complexity, and outcome requirements differ materially from commercial ASO. Non-ASO margins likely compressed vs ASO in the scale-up phase.
Internal cultural friction. Blind 3.3 and management approval 2.8 reflect real post-layoff damage. Product development velocity risk if R&D talent continues departing. This would show up in lagged product metrics, not in near-term client retention (97%).
Q1 FY26 beat-and-raise. If Q1 prints $185–190M (above $171–173M guide, consistent with $12–14M beat pattern), the 25% deceleration narrative collapses. Single most important near-term catalyst.
FY26 guidance raise. The gap between Q1 run-rate and the FY26 guide is too wide. A mid-year raise to $780–800M (33–36% growth) would drive multiple re-rating.
HingeSelect disclosure. Management deflected on Q4 utilization. Q1 or Q2 disclosure of HingeSelect scaling (provider count, referral volume, outcomes) validates the platform thesis.
Non-ASO to 15–20% of revenue. Proving the new payer channel at scale removes the ASO ceiling concern and extends the TAM narrative.
Sell-side initiation. HNGE is underfollowed for its quality profile. Post-IPO quiet period ended Nov 2025. GS/MS/JPM initiation reports with 12-month targets would bring institutional attention and reduce valuation gap.
Atlas does not hold HNGE as of the analysis date. Identified as a new position candidate. Conviction 4/5 — held back from 5/5 by limited post-IPO trading history (3 reported quarters) and FY26 guided growth deceleration uncertainty.